Vanover 2014.
Methods | Allocation: randomised.
Blindness: double blind. Duration: 28 days. Design: parallel. |
Participants | Diagnosis: acute exacerbated schizophrenia (DSM‐IV).
N = not reported.
Age: not reported.
Sex: not reported. Length of illness: not reported. Inclusion criteria: not reported. Exclusion criteria: not reported. |
Interventions | 1. Risperidone: 4 mg/d.
2. Placebo. 3. ITI‐007 60 mg/d. 4. ITI‐007 120 mg/d. |
Outcomes | Uable to use: PANSS, CDSS. |
Notes | No full text available, we contacted the author (Kimberly Vanover, Ph.D. kvanover@intracellulartherapies.com) but havn't received a reply yet. |